Sequence: Ac-YIGSR-AVA-LWRALWRLLRSLWRLLWKR-NH2
CRISPR RNA (Cas9 mRNA + sgRNA)
| Experiment Id | EXP002067 |
|---|---|
| Paper | Enhanced CRISPR-Cas9 RNA system delivery using cell penetrating peptides-based nanoparticles for eff |
| Peptide | ADGN-AVA |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 0.3–1 µg RNA |
| Mixing Ratio | R=20–200 |
| Formulation Format | Peptide-based nanoparticle |
| Formulation Components | ADGN-AVA + ADGN-PEG co-assembled with RNA |
| Size Nm | 130.00 |
| Zeta Mv | -7.80 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | A549-luc, MCF7-luc (multiple cancer cell lines) |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockout |
| Output Value | ≈50–60% luciferase knockdown (T7E1, qPCR) |
| Output Units | |
| Output Notes | Efficient CRISPR editing in vitro |
| Toxicity Notes | No cytotoxicity detected |
| Curation Notes |